Core Viewpoint - The company, Mei Yin Gene (06667.HK), reported a revenue of RMB 164 million for the fiscal year ending December 31, 2024, representing an 8.5% year-on-year growth, and a net profit of RMB 45 million, with a 50.0% increase in net profit compared to the previous year, driven by product innovation and market expansion strategies [1]. Group 1 - The company achieved a revenue of RMB 164 million, reflecting an 8.5% increase year-on-year [1] - The net profit reached RMB 45 million, showing a significant growth of 50.0% year-on-year [1] - The growth is attributed to the company's focus on product design innovation, enriching the product matrix, and optimizing product structure [1] Group 2 - The company has established partnerships with healthcare institutions in over 340 cities across China, enhancing its sales and marketing network [1] - The sales and marketing network enables the company to provide genetic testing services to a large portion of the Chinese population [1] - Collaborations with various e-commerce and online healthcare platforms have been initiated to expand and improve the sales and marketing network [1]
美因基因(06667.HK)2024年净利4500万元 同比增长50%